Celldex Therapeutics Limited

Avant Immunotherapeutics, Inc.

Lawrence J Thomas

Tibor P Keler

Lizhen He

Laura A Vitale

Joel Goldstein

Karuna Sundarapandiyan

Jenifer Widger

Tom O'Neill

Andrea Crocker

Henry C Marsh

Charles William Rittershaus

Kenneth Roland

Hua Gao

Xiaoxi Qiao

Kevin P Killeen

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Agonistic antibodies that bind human CD40 and uses thereof

Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Antibodies that bind human CD27 and uses thereof

Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies

Nucleic acids encoding agonistic antibodies that bind CD40

Agonistic antibodies that bind CD40

A method is disclosed for treating diseases or disorders of the eye involving undesired neovascularization by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1). The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering a complement inhibitory protein intraocularly or systemically.

Treatment for age-related macular degeneration and other diseases of the eye

Oral immunogenic compositions imparting dual protection against enterotoxigenic labile toxin (LT)-expressing(ETEC) andbased on the delivery of recombinant cholera toxin B antigen by attenuated, live bacterial vectors derived fromare disclosed. The compositions exhibit dual immunogenicity and retain the ability to colonize gastrointestinal mucosa-associated lymphoid tissues.

[object Object]

This invention relates to peptides comprising a helper T cell epitope portion and a B cell epitope portion for eliciting an immune response against endogenous cholesteryl ester transfer protein (CETP) activity, to prevent or treat cardiovascular disease, such as atherosclerosis.

Modulation of cholesteryl ester transfer protein (CETP) activity

A plasmid-based vaccine is provided herein based on the combination of DNA segments coding for one or more B cell epitopes of CETP and one or more broad range helper T cell epitopes. Administration of the plasmids as a vaccine to a vertebrate subject provides an immune response to the subject's endogenous CETP and modulation of CETP activity, leading to prevention or reversal of various manifestations of heart disease. The vaccines provide an advantageous strategy for the prevention or treatment of atherosclerosis.

Plasmid-based vaccine for treating atherosclerosis

Conjugates are disclosed comprising a broad range helper T cell epitope portion and a B cell epitope portion from a cholesteryl ester transfer protein (CETP), which conjugates are capable of eliciting an immune response in an individual against the individual's endogenous CETP activity. The conjugates are useful in methods to inhibit CETP activity, to raise serum levels of high density lipoproteins, and to prevent or treat cardiovascular disease, such as atherosclerosis.

A plasmid-based vaccine is provided herein based on the combination of DNA segments coding for one or more B cell epitopes of cholesteryl ester transfer protein (CETP) and one or more broad range helper T cell epitopes. Administration of the plasmids as a vaccine to a vertebrate subject provides an immune response to the subject's endogenous CETP and modulation of CETP activity, leading to prevention or reversal of various manifestations of heart disease. The vaccines provide an advantageous strategy for the prevention or treatment of atherosclerosis.

Growing community of inventors

Easton, MA, United States of America

Lawrence J Thomas